The major intervention in the LIFE pilot study for participants assigned to the exercise group will be walking. According to the treatment protocol, during the first six months as much as half of their increase in walking will be carried out at home or in a non-supervised setting. During the second six months, at least 75% of the assigned walking will be non-supervised for most participants. To know if this intervention was accomplished, LIFE investigators need documentation that a significant increase in walking took place in the exercise participants versus the healthy aging class participants. Currently the protocol includes the use of pedometers, logs and the CHAMPS questionnaire to inform the investigators about the activity profile of each study participant. While all of these measurement tools are likely to provide useful data, none have been proven to provide an accurate and objective assessment of the daily physical activity profile of older, somewhat frail persons. The Actigraph is a small solid-state accelerometer/recorder (6.6 x 4.3 x 2.5 cm., 70 grams) that can store the number of times it moves x the rate of movement change (acceleration) on a continuous basis for up to a month (approximate battery life). It stores these counts for specified times intervals, usually set at one-minute. For LIFE, this monitor will be worn on the right hip of each participant. The trial is now complete and actigraph data are being cleaned and analyzed. A paper on the results is in preparation.
| Ornstein, Katherine A; Zhu, Carolyn W; Bollens-Lund, Evan et al. (2018) Medicare Expenditures and Health Care Utilization in a Multiethnic Community-based Population With Dementia From Incidence to Death. Alzheimer Dis Assoc Disord 32:320-325 |
| Zhu, Carolyn W; Cosentino, Stephanie; Ornstein, Katherine A et al. (2017) Interactive Effects of Dementia Severity and Comorbidities on Medicare Expenditures. J Alzheimers Dis 57:305-315 |
| Lara, Elvira; Haro, Josep Maria; Tang, Ming-Xin et al. (2016) Exploring the excess mortality due to depressive symptoms in a community-based sample: The role of Alzheimer's Disease. J Affect Disord 202:163-70 |
| Zahodne, Laura B; Ornstein, Katherine; Cosentino, Stephanie et al. (2015) Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression. Am J Geriatr Psychiatry 23:130-40 |
| Tsapanou, Angeliki; Scarmeas, Nikolaos; Gu, Yian et al. (2015) Examining the association between Apolipoprotein E (APOE) and self-reported sleep disturbances in non-demented older adults. Neurosci Lett 606:72-6 |
| Tsapanou, Angeliki; Gu, Yian; Manly, Jennifer et al. (2015) Daytime Sleepiness and Sleep Inadequacy as Risk Factors for Dementia. Dement Geriatr Cogn Dis Extra 5:286-95 |
| Zhu, Carolyn W; Cosentino, Stephanie; Ornstein, Katherine et al. (2015) Use and cost of hospitalization in dementia: longitudinal results from a community-based study. Int J Geriatr Psychiatry 30:833-41 |
| Zhu, Carolyn W; Livote, Elayne E; Kahle-Wrobleski, Kristin et al. (2011) Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease. Alzheimer Dis Assoc Disord 25:144-8 |
| Zhu, Carolyn W; Livote, Elayne E; Kahle-Wrobleski, Kristin et al. (2010) Longitudinal medication usage in Alzheimer disease patients. Alzheimer Dis Assoc Disord 24:354-9 |
| Scarmeas, Nikolaos; Honig, Lawrence S; Choi, Hyunmi et al. (2009) Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 66:992-7 |
Showing the most recent 10 out of 12 publications
